By further comparison, we first raised that elevated TSG-6 levels were associated with 3-month poor prognosis of non-cardioembolic AIS, which was similar to the observation that with increased TSG-6 levels, myocardial infarction and major adverse cardiovascular events (MACE) were more likely to occur, including cardiovascular death, heart failure, acute myocardial infarction, post-infarction angina, and ischemic stroke in patients with acute coronary syndrome during a period of 4 years after onset (25). This evidence concerns the gene TNFAIP6 and myocardial infarction.